Dr. Avigan on CAR T-Cell Therapy in Lymphoproliferative Disease

Video

David E. Avigan, MD, discusses research surrounding CAR T-cell therapy in lymphoproliferative diseases.

David E. Avigan, MD, professor of medicine, Harvard Medical School, and active staff, Hematology-Oncology, Beth Israel Deaconess Medical Center, discusses research surrounding CAR T-cell therapy in lymphoproliferative diseases.

CAR T-cell therapy, according to Avigan, has been transformative in lymphoproliferative diseases such as acute lymphocytic leukemia and non-Hodgkin lymphoma. The approach is now being investigated in multiple myeloma with a focus on BCMA as a target, which is predominantly expressed in plasma cells.

The results with CAR T-cell therapy vary and have included some high response rates, including in patients with advanced disease. The next step is to examine the durability of these responses. One study with longer follow-up suggested a median time of response of 12 months, with a little duration of response in patients with advanced disease.

Avigan believes researchers need to make progress in understanding why patients are relapsing and what can be done to preserve response. Efforts to do so include investigating mechanisms of resistance and sequencing of CAR T-cell therapy, concludes Avigan.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.